Q1 2024 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2024-05-15 · accession 0001104659-24-061870
$917.4M
Reported value
15
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $188.3M | 20.5% | 2,360,077 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $144.5M | 15.8% | 1,924,626 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $136.1M | 14.8% | 2,048,647 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $82.9M | 9.03% | 2,762,837 | Common | SOLE |
| G5269C101 | — | KINIKSA PHARMACEUTICALS LTD | $63.2M | 6.89% | 3,204,841 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $56.3M | 6.14% | 3,202,798 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $50.0M | 5.45% | 3,554,129 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $32.3M | 3.52% | 1,845,813 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $32.3M | 3.52% | 717,254 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $31.8M | 3.46% | 4,725,641 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $27.0M | 2.94% | 931,890 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $22.9M | 2.49% | 1,393,329 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $22.0M | 2.40% | 6,666,667 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $14.4M | 1.56% | 378,421 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $13.4M | 1.46% | 2,040,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.